Form D · Pharmaceuticals
Eleos Pharmaceuticals, Inc.
Watkinsville, GA · CIK 0001885028
Offering snapshot reported Oct 1, 2021 · SEC filing
- Reported sold
- $500K Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $500K Reported outside-investor minimum
- First sale
- Aug 23, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 1, 2021 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-415377
Source: Form D, filed Oct 1, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher J. Elliott | Executive |
| David Sailors | Director |
| Jonathan Woody | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1357 Oconee Connector Building 300
Watkinsville, GA, 30677
Watkinsville, GA, 30677